Oxford BioDynamics collaborates with National Cancer Institute in prostate cancer clinical trial
Oxford BioDynamics Plc (AIM: OBD), a pioneering biotechnology company, has announced its participation in a significant clinical trial led by the National Cancer Institute (NCI) ... Read More
Oxford BioDynamics partners with Goodbody Clinic to enhance prostate cancer screening across UK
Oxford BioDynamics Plc, a leader in developing precision medicine tests, has partnered with Goodbody Clinic, a major provider of private health testing services in the ... Read More